Biosimilar Trends
Biosimilars represent both a significant opportunity and challenge for the biopharmaceutical industry. Download our trend report to learn more about […]
Blog, Maxor, MaxorPlus
Maxor
Blog, Maxor
Advances in Diabetes Treatment
In the United States, over 38 million people—roughly 1 in 10 Americans—are living with diabetes, a condition that impacts how
Blog, Maxor
Social Determinants of Health (SDOH) and Their Impact on Breast Cancer Medication Adherence
Maxor recently conducted a retrospective analysis of claims data to understand the impact of social determinants of health (SDOH) on
Blog, Maxor
4 Tips to Protect Your 340B Program Benefits
As a covered entity, you must protect your 340B program from manufacturers attempting to reduce savings and eligibility. Here are
Blog, Maxor, MaxorPlus
Cell and Gene Therapy
As the field of cell and gene therapy advances, new opportunities will emerge for healthcare stakeholders, including payers, providers, and
Blog, Maxor, Press Releases
New Research Reveals More Hospital and Health System C-Suites are Transforming Pharmacy Services in the Next 3-5 years
Leaders say they are turning the cost centers into revenue streams A newly released industry survey report from Maxor, a
Blog, Maxor
MaxorPlus Formulary Update: Biosimilars
We are changing our formulary list for 2025, moving to a biosimilar for a frequently prescribed medication, Humira®. This switch
Blog, Maxor
Nothing to cry about: Exploring the latest treatments for dry eye disease
Dry eye disease (DED) is a common medical condition, and according to the National Eye Institute, it affects about 16
Blog, Maxor, Press Releases
MaxorPlus Named Top Workplace for Fourth Year in a Row
Maxor proudly announces that its pharmacy benefit management division, MaxorPlus, has been honored with the Top Workplaces 2024 award by
Blog, Maxor
Drug Spotlight – July 2024
Introducing our Drug Pipeline Spotlight We’ve highlighted three groundbreaking drugs recently approved or pending approval from the FDA. Want to